Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0023473 (chronic myeloid leukemia)
 18,916 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

We encountered a 36-year-old woman, who developed two keratoacanthomas at rather a short interval after bone marrow transplantation for chronic myeloid leukemia. This skin disease seems to be associated with various factors, but its etiology still remains obscure. The fact that the patient was under postoperative immunosuppressive treatment suggests that, among other factors, a deterioration or an impairment of immunocapacity may play some role in the pathogenesis of keratoacanthoma. It is intriguing that two lesions appeared successively in one patient.
 ...
PMID:Keratoacanthoma ensuing from bone marrow transplantation for chronic myeloid leukemia. 152 82

Chronic myelogenous leukemia (CML) is characterized by a reciprocal translocation between the long arms of chromosomes 9 and 22 leading to the formation of a constitutively active tyrosine kinase. Tyrosine kinase inhibitors (TKIs) are the treatment of choice for patients diagnosed with CML and have many associated side effects including the rarely-reported eruption of squamous cell carcinomas (SCCs). Herein, we report a patient with CML who presented with sudden onset of multiple scaly lesions on his legs and trunk after beginning treatment with nilotinib, a novel TKI. Six biopsies were performed at his initial presentation and four of these lesions were confirmed to be keratoacanthoma-type SCCs. One month later, the patient reported the development of multiple new similar lesions on his legs, arms, and face. Four more biopsies were performed revealing keratoacanthoma-type and well-differentiated SCCs. Certain tyrosine kinase inhibitors such as sorafenib and quizartinib have been reported to cause eruptive keratoacanthoma (KA)-type SCCs as seen in our patient. However, there is only one other report in the literature of nilotinib promoting the development of SCCs or KAs. Physicians should be aware of this potential adverse effect and patients taking nilotinib should be closely monitored by a dermatologist.
 ...
PMID:Eruption of squamous cell carcinomas after beginning nilotinib therapy. 3281 90